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The  hereditary  inclusion-body  myopathies  encompass  several 
syndromes with autosomal recessive or dominant inheritance. 
Despite a different clinical presentation they all have a progres-
sive course leading to severe disability and share similar patho-
logic  findings  at  the  muscle  biopsy.  Quadriceps-sparing  auto-
somal  recessive  hereditary  inclusion-body  myopathy  (h-IBM) 
is the commonest form and is tied to mutations of the UDP-N-
acetylglucosamine  2-epimerase/N-acetylmannosamine  kinase 
(GNE) that codes for a rate-limiting enzyme in the sialic acid 
biosynthetic pathway. Despite the identification of the causative 
gene defect, it has not been clarified how mutations of the GNE 
gene impair muscle homeostasis. Although several lines of evi-
dence argue in favor of an abnormal sialylation of muscle glyco-
proteins playing a key role in h-IBM pathogenesis, others studies 
have demonstrated new functions of the GNE gene, outside the 
sialic acid biosynthetic pathway, that may also be relevant. This 
review illustrates the clinical and pathologic characteristics of h-
IBM and the main clues available to date concerning the possible 
pathogenic mechanisms of this disorder. Understanding the mo-
lecular mechanism underlying h-IBM pathology is a fundamen-
tal requisite to plan a future attempt to therapy.
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The  hereditary  inclusion-body  myopathies  encom-
pass several syndromes with autosomal recessive or dom-
inant inheritance. Despite a different clinical presentation 
they all have a progressive course leading to severe dis-
ability and share similar pathologic findings at the muscle 
biopsy. Quadriceps-sparing autosomal recessive heredi-
tary inclusion-body myopathy (h-IBM, IBM2, OMIM# 
600737) is the commonest form and was originally de-
scribed in patients of Persian Jewish (PJ) heritage (1, 2). 
Typically, h-IBM is characterized by onset in the second-
third decade of life with weakness and atrophy of distal 
lower limb muscles that eventually spreads proximally 
with a relative and selective sparing of the quadriceps. In-
volvement of upper limb muscles is observed in the more 
advanced stages of the disease (1). h-IBM is tied to mu-
tations of the UDP-N-acetylglucosamine 2-epimerase/N-
acetylmannosamine kinase (GNE) gene that codes for a 
bifunctional and rate-limiting enzyme (the UDP-GlcNAc 
epimerase/ManNAc kinase, GNE/MNK) in the sialic acid 
biosynthetic cascade (3, 4). h-IBM patients of PJ descent 
share a common founder mutation consisting in a T to 
C shift at nucleotide position c.2135 of the GNE gene 
that results in a methionine to threonine change at codon 
712 (p.M712T) (3), whereas affected individuals of dif-
ferent ethnicities are usually compound heterozygous or 
homozygous for different mutations (5-10). Shortly after 
the identification of the h-IBM causative gene defect, mu-
tations of the GNE gene have been demonstrated to be re-
sponsible also for distal myopathy with rimmed vacuoles 
or Nonaka myopathy (DMRV, OMIM# 605820) (11, 12), 
a disorder described in Japanese patients and character-
ized by clinical and pathologic features remarkably simi-
lar to h-IBM, thus proving that h-IBM and DMRV are in-
deed the same entity as previously suggested by Askanas 
and Engel (13). To date more than 50 mutations distrib-
uted throughout the GNE gene and associated to h-IBM 
have been described worldwide.
As  previously  sketched  out,  the  h-IBM  canonical 
phenotype is characterized by onset in late teenage or 
early adulthood years with initial distal muscle weakness 
and subsequent disto-proximal progression. Distinctively 
in this disorder, the quadriceps muscles retain a normal or 
close-to-normal strength even when other muscle com-
partments  become  severely  affected.  Nonetheless,  the 
identification of the causative gene defect has allowed 
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the recognition of phenotypic variants, such as patients 
lacking distal weakness or with unusual quadriceps in-
volvement (2, 14). On the contrary, it has been shown that 
sparing of the quadriceps is not unique to h-IBM as it 
has also been reported in patients affected by a non-GNE-
related myopathy (15). Furthermore, the age at onset of 
symptoms is sometimes postponed even to late adulthood 
as isolated patients, carrying either the p.M712T or the 
p.A578T mutations and still asymptomatic in their 6th-7-
th decade of life, have also been described (2, 11). This 
collection  of  evidence  leads  to  diverse  considerations. 
First, the prevalence of this disorder in patients of non-PJ 
inheritance is probably higher than what previously as-
sumed, as numerous cases with atypical presentation may 
remain undiagnosed. Moreover, a wider range of clinical 
phenotypes associated with GNE mutations would sug-
gest that different mutations are not functionally equiva-
lent, id est different mutations may differently impact cell 
metabolism and viability. Contrariwise, the fact that a dif-
ferent clinical course can be observed in patients harbor-
ing the same mutations argue in favor of epigenetic fac-
tors conditioning the phenotypic outcome. However, no 
conclusive genotype-phenotype studies are available to 
date. Finally, the selective involvement of skeletal muscle 
is particularly puzzling in consideration of the fact that 
this tissue expresses relatively low levels of the enzyme 
in comparison to other tissues, like liver, lung and kidney, 
that remain unaffected (16). This suggests the existence 
of putative susceptibility factors of skeletal muscle to a 
generalized metabolic impairment.
Morphologic abnormalities of h-IBM muscle biopsy 
include i) increased scatter of muscle fiber diameter and 
centralization of myonuclei, ii) muscle fibers with rimmed 
vacuoles, iii) intracytoplasmic and intranuclear filamen-
tous  inclusions  by  electron  microscopy,  and  iv)  vari-
able amount of angulated atrophic fibers. The molecular 
phenotype of h-IBM muscle remarkably resembles that 
of sporadic inclusion-body myositis (s-IBM), the most 
frequent myopathy occurring in elderly patients. In fact, 
besides the presence of muscle fibers bearing cytoplas-
mic “rimmed vacuoles”, in both disorders there is the ab-
normal accumulation of an array of proteins commonly 
associated with Alzheimer’s disease brain pathology in-
cluding Amyloid β (Aβ) and paired helical filaments con-
taining hyperphosporylated tau (13). Although in isolated 
h-IBM cases the presence of muscle perimysial or en-
domysial collection of inflammatory cells has also been 
reported (2, 17, 18), the key pathologic features differen-
tiating h-IBM muscle from that of s-IBM include the lack 
of inflammation and congophilic inclusions within the 
muscle fibers (19, 20). The similarities between the mo-
lecular features of h-IBM and s-IBM suggest that, despite 
different etiologies, possibly both disorders share some 
common downstream pathogenic mechanisms leading to 
progressive muscle fiber degeneration (21).
To date the cellular pathogenic mechanism activated 
by mutations of the GNE gene is far to be elucidated. Sial-
ic acid is a monosaccharide decorating the terminal ends 
of the glycan chains of glycoproteins. Differential sialyla-
tion of cell surface molecules is crucial for their functions 
in physiological as well as pathological processes (4). An 
object of controversy is whether GNE mutations lead to 
reduced sialylation of muscle glycoproteins and this has a 
pivotal role in h-IBM pathogenesis. The GNE/MNK has 
two functionally independent domains and it has been 
shown that the selective targeting of the epimerase do-
main of the enzyme does not affect the kinase active site 
and vice versa (22, 23). A reduction of the epimerase ac-
tivity has been demonstrated in lymphocytes from h-IBM 
patients, thus suggesting a partial loss of function of the 
enzyme (11). In addition, it has been shown by in-vitro 
experiments that two independent lines of Lec3 Chinese 
hamster ovary cell glycosylation mutants, carrying either 
a nonsense p.E45stop or a p.G135E missense mutations in 
the GNE gene, lack UDP-GlcNAc epimerase activity and 
have extremely low levels of polysialylated-neural cell 
adhesion molecule (PSA-NCAM) on the cell surface (24). 
In keeping with this line of evidence is the fact that a 
transgenic mouse model expressing the human GNE gene 
with the p.D176V mutation on a GNE knockout back-
ground is characterized by a reduced level of sialic acid in 
serum and other tissues and develops a myopathy that re-
sembles h-IBM (25). Moreover, in this animal model the 
prophylactic supplementation of sialic acid metabolites 
prevents the development of the myopathic phenotype, 
thus strengthening the hypothesis that a reduced amount 
of cellular sialic acid underlies disease pathogenesis (26). 
However, to date few clues are available regarding specif-
ic proteins or cellular processes whose function becomes 
impaired following this metabolic defect. We have previ-
ously shown an abnormal, although inconsistent among 
different h-IBM patients, sialylation of α-dystroglycan 
(α-DG), a structural protein that provides a connection 
between  proteins  of  the  cellular  cytoskeleton  and  the 
extracellular matrix such as laminin (27). Provided that 
such abnormality does not impact the capacity of α-DG 
to bind laminin, we believe that the abnormal sialylation 
of α-DG does not have a relevant role in the pathogenic 
cascade activated in h-IBM muscle.
We have also shown that in h-IBM muscle NCAM is 
consistently hyposialylated and this results in increased 
electrophoretic mobility of the protein by sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis. Indeed, by 
western blot analysis in h-IBM muscle NCAM appears 
as a sharp band of approximately 130 kDa rather than a 
broader band with a molecular weight ranging between Hereditary inclusion-body myopathy with sparing of the quadriceps: the many tiles of an incomplete puzzle
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150 and 200 kDa as observed in all other myopathies (15). 
The  possible  pathogenic  relevance  of  hyposialylated 
NCAM in h-IBM is not known. PSA-NCAM has a role 
in NMJ physiology (28) and this is potentially interest-
ing in view of the fact that in vitro cultured primary h-
IBM myotubes cannot be innervated by neuritis emerging 
from rat spinal cord fragments, thus suggesting a mecha-
nism of “myogenous dysreception to innervation” (29). 
Whether hyposialylated NCAM plays some role in this 
abnormality remains to be elucidated. Nonetheless, de-
spite a possible role in h-IBM pathogenesis, in our experi-
ence hyposialylated NCAM can be used as a pre-genetic 
cellular marker to identify patients with a GNE-related 
myopathy in the routine diagnostic workup of muscle bi-
opsy in the laboratory. This can be helpful to differentiate 
h-IBM patients from others affected by a phenotypically 
similar myopathy not due to mutations of the GNE gene 
or to identify h-IBM patients with uncommon clinical or 
pathologic features (14).
Furthermore, we have demonstrated that the expres-
sion and enzymatic activity of neprilysin (NEP), a sialo-
glycoprotein capable of cleaving Aβ at multiple sites, are 
reduced in h-IBM muscle, possibly in connection with its 
abnormal sialylation. In fact, we have found that in vitro 
the enzymatic removal of sialic acid from muscle glyco-
proteins results in reduced expression and enzymatic ac-
tivity of NEP along with the intracytoplasmic accumula-
tion of Aβ (30). We do not know whether this functional 
defect of NEP is per se sufficient to trigger Aβ accumula-
tion. In fact, h-IBM muscle is also characterized by in-
creased expression of the Aβ precursor protein possibly 
due to the abnormal cellular mechanisms connected with 
mutations of the GNE gene (19, 31, 32). However, in the 
complex and still undisclosed scenario of h-IBM muscle, 
it is possible that hyposialylated and dysfunctional NEP 
has a role in hampering the cellular Aβ clearing system, 
thus contributing to its accumulation within vulnerable 
fibers.  How  hyposialylation  of  NEP  affects  its  stabil-
ity is not known, although interference with the correct 
processing of the protein in the endoplasmic reticulum 
(ER) leading to a more rapid degradation can be hypoth-
esized. In normal conditions nascent proteins destined for 
the secretory pathway are translocated from the cytosol 
into the ER and then engaged in the folding machinery, 
which aids in achievement of the native conformation, 
posttranslational  modifications  and  multimeric  protein 
assembly (33). Such a complex protein processing is sub-
jected to a stringent quality control system so that defec-
tive and misfolded proteins remain in the ER and then 
degraded  through  the  ER-associated  degradation  proc-
ess (34). Changes in cellular homeostasis, involving for 
example the redox status or glycosylation mechanisms, 
can result in accumulation of unfolded or misfolded pro-
teins within the ER, thus leading to a condition of ER 
stress (34, 35). Once ER stress condition is established, 
the misfolded and unfolded proteins trapped in the ER 
are retrotranslocated to the cytoplasm and degraded by 
the ubiquitin-proteasome system (36). It has been already 
established that ubiquitinated proteins accumulate within 
h-IBM muscle fibers, thus strengthening the hypothesis 
that an abnormal protein processing does indeed play a 
role also in this disorder (21, 37). In general terms, the 
possibility exists that, in h-IBM, hyposialylation of glyc-
oproteins may perturb their proper folding and trafficking 
through the ER and Golgi network and the translocation 
to the plasma membrane. This would activate a mecha-
nism of ER stress that is intended to manage the accumu-
lation of abnormal proteins. Once a ER stress condition is 
established, the misfolded and unfolded proteins trapped 
in the ER are retrotranslocated to the cytoplasm and de-
graded by either the ubiquitin-proteasome system or the 
autophagic process (38). Nevertheless, further studies are 
necessary to verify this hypothesis.
Another line of reasoning pursued so far is that hy-
posialylation  of  muscle  glycoproteins  represents  only 
a minor byproduct of a metabolic impairment that may 
instead crucially affect other subcellular compartments. 
In vitro studies have shown that GNE/MNK is able to in-
teract with factors such as the collapsin response media-
tor protein 1 and the promyelocytic leukemia zinc finger 
protein (39), but none of these proteins has been proven 
so far to be involved in the pathogenic cascade of h-IBM 
muscle. More recently, GNE/MNK has also been demon-
strated to partially co-localize with α-actinin 1 in the sar-
comere of mature muscle fibers. However, such evidence 
does not appear relevant to h-IBM pathophysiology as, in 
vitro, no gross difference has been observed between the 
interaction of α-actinin 1 with wild type GNE/MNK and 
mutated GNE/MNK, respectively (40).
In  h-IBM  the  terminating  cellular  process,  either 
necrotic or apoptotic, that is primarily responsible for the 
progressive reduction of muscle bulk, has not been une-
quivocally elucidated. Indeed, h-IBM muscle fiber necro-
sis is infrequently found and features of apoptosis have so 
far only an anecdotic relevance (41, 42). Nonetheless, a 
possible role of mutated GNE/MNK in the activation of 
the apoptotic cascade has recently arisen by showing that 
in vitro cultured primary h-IBM muscle cells are more 
prone to staurosporine-induced apoptosis possibly in con-
nection with an intrinsic impairment of the insulin-like 
growth factor-I/Akt pathway (43). Nevertheless, an un-
ambiguous demonstration that apoptotic mechanisms are 
activated in h-IBM muscle biopsies is still missing
A recent work has shown that GNE/MNK regulates 
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GD3 gangliosides, respectively (44). Interestingly, GM3 
and GD3 gangliosides regulate the mRNA level of BiP, a 
master regulator protein involved in ER stress as well as 
in other cellular processes such as proliferation, senes-
cence and apoptosis (45-47). More in detail, GD3 elicits 
production of reactive oxygen species from complex III 
of the mitochondrial electron transport chain that leads 
to the opening of the mitochondrial permeability transi-
tion pore and the activation of cytochrome c-dependent 
caspase 3 (48). Nevertheless, the molecular mechanisms 
through which GNE/MNK influences the level of expres-
sion of GM3 and GD3 gangliosides are not understood 
and, more importantly, no studies have been conducted 
on how this functional relationship becomes modified by 
mutations of the GNE gene.
If future studies prove that GNE/MNK has a role in 
cellular pathways other than that of sialic acid and possi-
bly more relevant for maintaining skeletal muscle home-
ostasis, then this will also provide valuable clues to under-
stand the specific susceptibility of muscle to a generalized 
metabolic impairment that is peculiar of h-IBM.
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